Safety of Vedolizumab in Pregnancy
Vedolizumab exposure during pregnancy in individuals with IBD was not associated with increased odds of early pregnancy loss, congenital malformations, or composite perinatal complications. However, increased odds of preterm birth and cesarean delivery were observed, potentially reflecting underlying disease severity.
Authors
- Astrid‐Jane Williams (ORCID: https://orcid.org/0000-0002-1756-5329)
- Bachviet Nguyen (ORCID: https://orcid.org/0000-0002-9177-7039)
- Yvette Leung
- Stephanie Quon (ORCID: https://orcid.org/0000-0001-9188-8380)
Institutions
- University of British Columbia (CA)
- Vancouver Infectious Diseases Centre (CA)
Publication Details
- Journal
- Journal of Clinical Gastroenterology
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1097/mcg.0000000000002310
- Primary Topic
- Pregnancy and Medication Impact
- Type
- article
- Field-Weighted Citation Impact
- 0.00